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Abstract 
Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 
subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-
one series was designed to rationally exploit these residue differences between the histone 
substrate binding sites in order to improve affinity for the KDM4-subfamily over KDM5-
subfamily enzymes. In particular, residues E169 and V313 (KDM4A numbering) were 
targeted. Additionally, the conformational restriction of the flexible pyridopyrimidinone C8-
substituent was investigated. These approaches yielded potent and cell-penetrant dual 
KDM4/5-subfamily inhibitors including 19a (KDM4A and KDM5B Ki = 0.004 and 0.007 
µM, respectively). Compound cellular profiling in two orthogonal target engagement assays 
revealed a significant reduction from biochemical to cell-based activity across multiple 
analogues; this decrease was shown to be consistent with 2OG competition, and suggest that 
sub-nanomolar biochemical potency will be required with C8-substituted pyrido[3,4-
d]pyrimidin-4(3H)-one compounds to achieve sub-micromolar target inhibition in cells. 
 
 
 
 
 
 
 
Keywords: 
pyridopyrimidinones, KDM4 subfamily, KDM5 subfamily, KDM inhibitors, histone 
demethylases   
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1. Introduction 
Human Jumonji C-domain (JmjC) histone lysine demethylases (KDMs) are Fe(II) and 2-
oxoglutarate (2OG)-dependent oxygenases that demethylate mono-, di-, and trimethyl histone 
lysine substrates [[1], [2]]. They comprise five subfamilies varying in domain architecture but 
sharing a well conserved catalytic site [3]. Since the reporting of the first JmjC histone lysine 
demethylase in 2006 [[4], [5]], the JmjC KDMs have emerged as important players in 
maintaining chromatin architecture and regulating transcription [6]. 
The KDM4 subfamily consists of six members (A-F) that demethylate histone tail substrates, 
most notably di-, and tri-methylated lysine 9 (H3K9Me3/Me2) and lysine 36 
(H3K36Me3/Me2) on histone 3 [[6], [7]]. As well as the JmjC catalytic domain, KDM4 
subfamily enzymes contain a JmjN domain [6]; KDM4A-C also possess PHD and Tudor 
methyl-lysine reader domains. It has been suggested that PHD and Tudor domains could 
stimulate KDM-driven demethylation via the recognition of histone substrates [[8], [9]]. 
KDM4 subfamily members have been implicated in a number of human cancers, including 
promoting growth and cell survival in acute myeloid leukemia [10] and as regulators of ER-
dependent breast cancer cell growth [[11], [12]]. High expression of KDM4B in MYCN-
amplified neuroblastomas is associated with poor prognosis [13], and overexpression of 
KDM4A is reported to promote site-specific copy number gain (e.g. 1q12) [14]. In addition, 
KDM4A is reported to promote prostate cancer initiation through the transcription factor 
ETV1 [15]. 
The human KDM5 subfamily, which consists of four members (A-D), is structurally the most 
closely related to the KDM4 subfamily and also contains a JmjN domain. KDM5 enzymes 
catalyse demethylation of H3K4Me3/Me2 histone lysine substrates and are implicated in 
various types of human cancers [[16], [17], [18]]. A requirement for KDM5A has been 
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reported in drug tolerant human tumor cells [19], while KDM5B and KDM5C have been 
implicated in breast [[20], [21]] and prostate cancers [22], respectively. Also Dalvi et al 
recently reported that taxane-platin resistant lung cancer cells showed hypersensitivity to JIB-
04 (a pan-selective JmjC KDM inhibitor) and the KDM5/KDM6 subfamily inhibitor GSK-J4 
[23].  
 
Figure 1: Reported KDM inhibitors 
These findings have generated considerable interest in small-molecule inhibitors of KDM 
demethylase functions [24]. Early inhibitors of JmjC KDMs, such as the pyridine carboxylic 
acid-based analogues 1 and 2 (Figure 1) [[25], [26]] display pan - JmjC histone demethylase 
inhibitory activity, and feature a carboxylic acid which may hinder cell permeability [27]. 
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More recently, a range of structurally diverse JmjC KDM inhibitors has been reported with 
evidence of selective inhibition of specific KDM subfamilies. For example, the 
pyridopyrimidinone derivatives 3 and 4 (Figure 1) show selective inhibition of both KDM4 
and KDM5 subfamilies over members of KDM2, 3, or 6 demethylases [[28], [29]]. 
Compounds 5, 6, and 7 (Figure 1) selectively inhibit KDM5 subfamily members [[30], [31], 
[32]], and compound 8 (Figure 1) has recently been reported as a potent KDM4 subfamily 
inhibitor with promising selectivity [33]. In addition, a chemoproteomics approach revealed 
compound 9 as a selective KDM4 subfamily inhibitor [34]. Covalent inhibitors of KDM5 
subfamily have also been recently reported [[35], [36]]. In addition, a rhodium(III) complex 
has been reported as a selective inhibitor of KDM5A [37]. 
We previously reported the discovery of C8-substituted pyridopyrimidinones (e.g. 4) as a 
potent, cell penetrant dual KDM4 and KDM5 inhibitors [29]. Determination of the crystal 
structures of the mono m-Cl counterpart of 4 in complex with both KDM4A and KDM5B 
allowed us to identify residue differences in the histone substrate binding site that could be 
exploited for selective KDM4 subfamily inhibition. Herein, we report our efforts to gain 
selectivity for KDM4 over KDM5 subfamily inhibition by targeting residues V313 
(KDM4A) and E169 (KDM4A). We also report our attempts to reduce the conformational 
flexibility of the C8-substituent to improve KDM inhibitory activity and investigate the 
impact of such changes on KDM4 versus KDM5 selectivity. Finally, we demonstrate cell-
based target engagement for exemplar compounds from the 2-OG-competitive 
pyridopyrimidinone series and reveal a consistent drop off from in vitro biochemical to cell-
based activity.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
 
 
2. Chemistry 
 
aReagents and conditions: (a) (i) methanesulfonic anhydride, anhydrous CH2Cl2, 0 °C, 15 
min, work-up, (ii) triethylamine, C4-substituted piperidine, anhydrous DMF, 50 °C, 15 h; (b) 
C4-substituted piperidine, anhydrous 1,2-dichloroethane or CH2Cl2, NaBH(OAc)3, room 
temp.; (c) 6 M HCl, THF, 50 to 60 °C, 3 to 8 h or 4 M HCl in dioxane, H2O, 50 °C. 
 
Compounds 16b-m (Table 1), 17a-g (Table 2), 18b-c (Table 3), and 19a-d (Table 4) were 
prepared from key intermediates 10 and 11 via methods A and B, respectively as previously 
described for the synthesis of closely related analogues (Scheme 1) [29].  
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aReagents and conditions: (a) aryl/heteroaryl halide, Pd(dppf)Cl2, DME, 1 M aqueous 
Na2CO3, microwave, 120 °C, 45 min; (b) (i) Pd(OH)2 on carbon, EtOH, 1 M HCl, H2, room 
temp 1 h or 10% Pd/C, EtOH, H2, room temp, 2 h, (ii) when R = Boc: 4 M HCl in dioxane, 
room temp, 2 h or when R = Cbz: AcOH, 10% Pd/C, H2, room temp, 4 to 6 h. 
 
The key C4-substituted piperidine intermediates required for the SN2 displacement or 
reductive amination reactions to prepare 12b-m, 13a-g, 14b-c, and 15a-d (see Scheme 1) 
were commercially available or obtained as shown in Scheme 2. N-Protected 
tetrahydropyridine-4-boronic acid pinacol ester was reacted with appropriately substituted 
aryl/heteroaryl halides under Pd-catalysed conditions to provide intermediates 22e-h, 22j, 
22l,m, 23a, 23e-g and 24b,c (Scheme 2). Appropriately substituted aryl/heteroaryl halides 
were commercially available or readily synthesised via standard transformations as detailed 
in the experimental procedure (see Supporting Information). Reduction of the double bond 
followed by the removal of the N-protecting group afforded the desired C4-substituted 
piperidines (Scheme 2).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
 
aReagents and conditions: (a) (i) LiN(SiMe3)2 (1M solution in THF), THF, 0 °C, 45 min, (ii) 
tert-butyl bis(2-chloroethyl)carbamate, 0 °C, 2 h; (b) 10% Pd/C, EtOH, H2, room temp, 2 h; 
(c) 4 M HCl in dioxane, room temp, 2 h. 
 
The spirocyclopiperidine 30 required for the synthesis of 19b (Table 4) was accessed by 
reacting 4,7-dimethyl-1H-indene with lithium bis(trimethylsilyl)amide and tert-butyl bis(2-
chloroethyl)carbamate followed by the hydrogenation of the double bond in 29, and finally, 
removal of the Boc protecting group under acidic conditions (Scheme 3).  
 
aReagents and conditions: (a) aldehyde, NaBH(OAc)3, DMF, room temp, stirring up to 6 h; 
(b) Cs2CO3, anhydrous MeCN, 8-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-
d]pyrimidin-4(3H)-one, reflux, 18 h; (c) 6 M HCl, THF, 50 to 60 °C, 3 to 8 h. 
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Access to conformationally constrained pyrazole-C4 compounds 34b-h (Scheme 4, Table 5) 
was achieved by reductive amination of the relevant aldehyde by piperidine derivative 31 
followed by the introduction of the substituted pyrazole moiety 32 at the C8-
pyridopyrimidinone position via a SNAr displacement reaction, and removal of the SEM 
protecting group under acidic conditions (Scheme 4).  
Scheme 5
a
H
N
N
N
a b
H
N
N
N
H
N
N
Br
35 36 37
 
aReagents and conditions: (a) (i) 2.5 M nBuLi in hexane, THF, -78 °C to room temp (1.5 h) 
then cool to -78 °C, (ii) 1-methylpiperidin-4-one, warm up to room temp, 1.5 h, then 
AcOH/TFA, 90 °C, 4 h; (b) 10% Pd/C, EtOH, 1 M HCl, H2, 16 h. 
 
Preparation of 1-methyl-4-(1H-pyrazol-4-yl)piperidine (37), required for the synthesis of 34a 
(Table 5) was carried out using an alternative approach whereby 4-bromopyrazole (35) was 
reacted with nBuLi followed by the addition of 1-methylpiperidin-4-one. Subsequent 
dehydration of the addition product under acidic conditions followed by hydrogenation of the 
double bond in 36 afforded 37 (Scheme 5). The incorporation of the piperidine 37 at the C8-
pyridopyrimidinone position was achieved via a SNAr displacement reaction as described for 
analogues 33b-h (Scheme 4), and the SEM protecting group was removed by treatment with 
TBAF in THF. 
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aReagents and conditions: (a) triethylamine, anhydrous DMF, 50 °C, 15 h; (b) 6 M HCl, THF, 
50 °C, 3 h. 
 
Access to 41, a matched-pair inactive control for 19a, was achieved upon treatment of the 
mesylate 38, prepared as previously described [38], with spirocyclopiperidine 39 and 
triethylamine in DMF followed by the removal of the SEM protecting group of 40 under 
acidic conditions (Scheme 6). 
3. Results and Discussion 
We recently reported a series of C8-substituted pyridopyrimidinone derivatives, with the 
most advanced analogues, such as 4 (Figure 1) and 16a (Table 1), demonstrating selective 
and equipotent inhibition of KDM4 and KDM5 over the KDM2, KDM3, and KDM6 
subfamilies [29]. 
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Figure 2: Overlay of crystal structures of 16a bound to KDM4A (light orange), and KDM5B 
(cyan). Compound 16a is shown in ball and stick representation and protein backbone chains 
are represented as cartoon tubes, with key amino acid side-chains displayed in line 
representation. Metal ions are shown as spheres. Labels highlight residues that are different 
between KDM4A (black) and KDM5B (cyan). KDM5B loop 91-100 is not displayed due to 
its construct-derived artefactual position as discussed in Figure S1. 
To identify potential interactions that could increase KDM4 subfamily potency and 
selectivity over KDM5 subfamily enzymes, we determined the crystal structures of 16a in 
complex with KDM4A and KDM5B (Figure 2). In the KDM4A-bound structure, the C4-
pyrazole substituent of 16a extends into the histone substrate binding site and towards the 
surface of the enzyme (Figure S2); the m-Cl substituent on the phenyl group makes 
hydrophobic contact with V313 of KDM4A (Figure 2), a residue that is conserved across all 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
KDM4 subfamily members (Figure S3). We postulated that this favourable hydrophobic 
interaction with V313 contributes to the increased KDM4 inhibitory profile of 16a compared 
to the KDM5-preferring profile of earlier analogues in this series [29]. In addition, 16a is a 
more potent inhibitor of both KDM4A and KDM4B than its unsubstituted phenyl counterpart 
(compound 54g in reference 29) consistent with the observed hydrophobic interaction of the 
m-Cl substituent. Furthermore, the crystal structure of 16a bound to KDM5B indicated no 
residue equivalent to KDM4A V313 due to a different protein fold (Figure 2). This 
observation further supports the hypothesis that the hydrophobic contact of the m-Cl 
substituent in 16a with V313 increases KDM4 inhibitory activity leading to a balanced 
KDM4/5 inhibitory profile.  
 
Figure 3: A) Overlay of crystal structures of 1 (2,4-PDCA, blue, PDB 2VD7) and 16a 
(beige) bound to KDM4A. B) Overlay of crystal structures of 1 (2,4-PDCA, orange, PDB 
5A3W) and 16a (cyan) bound to KDM5B. Metal ions are shown as spheres. Protein 
backbone chains are represented as cartoon tubes, key residues are displayed in line 
representation. Compounds 1 (2,4-PDCA) and 16a are shown in ball and stick representation. 
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KDM5B loop 91-100 is not displayed due to its construct-derived artefactual position as 
discussed in Figure S1.  
A more detailed study of the 16a-bound KDM5B crystal structure revealed additional 
residues close to the m-chlorophenyl moiety of the bound inhibitor that could be exploited to 
enhance KDM4-subfamiliy selectivity (Figure 2). For example, C480 is a serine residue in all 
other KDM5 subfamily members, and a glutamate in the KDM4 subfamily (E169 in 
KDM4A, Figures 2, S3 and S4). This suggests a potential for differential KDM4 versus 
KDM5 targeting although we recognised that exploiting selective interaction with the side 
chain of E169 (KDM4A numbering) might be challenging due to its solvent exposed location 
and high mobility; for example, the side chain of E169 could be not associated to any 
electron density in the 16a-bound KDM4A crystal structure. W486 in KDM5B is conserved 
across the KDM5 subfamily whilst the equivalent residue in the KDM4 subfamily is a 
tyrosine (Y175 in KDM4A, Figures 2, S3 and S4). However, the potential to exploit this 
difference is limited due to the similarity of tryptophan and tyrosine residues. We also 
observed that A430 in KDM5B is an asparagine residue in KDM4A (N137, Figure 2). 
However, these residues are not conserved within their respective subfamilies. N137 in 
KDM4A corresponds to S138 in KDM4B, S141 in KDM4D, and N139 in KDM4C (Figure 
S3), whilst A430 in KDM5B corresponds to S414 in KDM5A, and to H445/H435 in KDM5C 
and KDM5D, respectively (Figure S4), rendering exploitation of such differences for KDM4 
over KDM5 subfamily selective inhibition challenging. 
Based on these structural insights, we decided to further explore the favourable hydrophobic 
contact with V313 (KDM4A) to increase affinity and selectivity for the KDM4 over KDM5 
subfamily. As an alternative approach, we also considered the introduction of a basic 
substituent at either the m- or p-position of the phenyl ring in 16a to target E169 (KDM4A). 
We recognised that achieving selective KDM4- over KDM5-subfamily inhibition may be 
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challenging due to protein flexibility in the histone substrate binding site, as exemplified by 
induced-fit movement observed in C8-substituted pyrido[3,4-d]pyrimidin-4-one-bound 
KDM4A and KDM5B crystal structures compared with small 2OG-competitive inhibitors 
such as 1 (Figure 3). For example, the pyrazole C4-substituent in 16a induces movement of 
Y175 and nearby loop 160-171 of KDM4A, such that residues 162-169 become too mobile to 
be observed in the electron density map. In the KDM5B-16a crystal structure, W486 and 
nearby loop 426-435 are displaced relative the corresponding compound 1-bound structure, 
and an alternative conformation is observed for residues 479-482. We also recognised that 
conformational flexibility of the ligand pyrazole C4-substituent may adversely impact KDM 
inhibition and subfamily selectivity.  
Table 1.  4-Phenylpiperidine  derivatisation: m-Phenyl substitutiona  
                                                      
Compound 
 
       X KDM4A 
IC50 (µM) 
KDM4B 
IC50 (µM) 
KDM5B 
IC50 (µM) 
KDM5C 
IC50 (µM) 
Caco-2  
(x10-6 
cm/s) 
16ab    Cl 0.102± 
0.058 
0.031± 
0.012 
0.023 0.065 11.80 
16b 
 
   F 0.084± 
0.019 
0.032± 
0.016 
0.029 0.096 11.63 
16c 
 
   
tBu 0.141 0.049± 
0.041 
0.025c 
 
0.063c 
 
4.67 
16d 
 
  OMe 0.212± 
0.013 
0.067± 
0.036 
0.023 0.086 not 
tested 
16e 
   
0.178 0.101 0.051c 0.156c 10.77 
16f 
  
0.282 0.145 0.066c 0.213c not 
tested 
16g 
 
0.136 0.033± 
0.012 
0.042c 0.079c not 
tested 
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16h 
 
0.056 0.027± 
0.014 
0.017c 0.059c < 1.73 
16i 
 
0.088± 
0.046 
0.047± 
0.024 
0.021c 0.054c <1.52 
16j 
 
 
0.083± 
0.049 
 
0.019± 
0.013 
 
0.012 
 
0.030 
 
<0.76 
16k 
 
 
0.259 
 
0.063± 
0.023 
 
0.048c 
 
0.113c 
 
not 
tested 
16l 
 
0.059 0.015 0.012c 0.035c <0.92 
16m 
 
0.038± 
0.006 
0.008 0.006c 0.014c <1.52 
aResults are mean values of two independent determinations or mean (±SD) for n>2 unless 
specified otherwise. bData taken from reference 29. cResults are from a single experiment.  
 
Both fluoro and tert-butyl substitutions (compounds 16b and 16c, respectively) resulted in 
similar KDM inhibitory activities to those observed for the m-Cl counterpart 16a (Table 1). 
The methoxy and isopropyl derivatives 16d and 16e proved marginally inferior KDM4 
subfamily inhibitors compared to 16a, and a similar trend was also observed with the 
introduction of a bulkier alkoxy substituent (16f, Table 1).  
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Figure 4: Overlay of crystal structures of 16m (green) and 16a (beige) bound to KDM4A. 
Protein backbone chains are represented as cartoon tubes, key residues are displayed in line 
representation. Compounds 16m and 16a are shown in ball and stick representation. The two 
methyl groups in 16m have not been modelled due to too weak density linked to the high 
mobility of the corresponding atoms. Metal ions are shown as spheres.  
The introduction of 6-membered heterocyclic substituents (compounds 16g-i) was tolerated 
but with no evidence for selective KDM4 subfamily inhibition (Table 1). Some of the most 
active inhibitors incorporated a basic substituent at the m-position of the phenyl ring; notably 
pyrrolidine and dimethylamino derivatives 16j and 16m, respectively (Table 1). Consistent 
with previous findings [29], these m-substituted analogues retained selectivity over other 
KDM subfamilies; for example, 16j displayed weaker inhibition of KDM2A (IC50 = 1.97 
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µM), KDM3A (IC50 = 1.85 µM), and KDM6B (IC50 = 32.26 µM). Likewise, 16b displayed 
selectivity over KDM2A (IC50 = 4.68 µM), KDM3A (IC50 = 6.42 µM), and KDM6B (IC50 > 
100 µM). The crystal structure of 16m bound to KDM4A confirmed a direct but suboptimal 
interaction between the amino group of the m-substituent and the side chain of residue N137 
(distance of 3.2Å, Figure 4), consistent with the improved KDM4A potency of 16m (0.038 
µM) compared to the unsubstituted parent (54g in reference 29; KDM4A IC50 = 0.456 µM). 
Overall, 16m shows a balanced KDM4/KDM5 subfamily inhibitory profile whereas the 
unsubstituted parent compound (54g in reference 29; KDM5B IC50 = 0.058 µM) is KDM5B 
preferring. However, direct interaction of the basic substituent with KDM4A E169 was not 
observed by X-ray crystallography, likely due to the high mobility of the E169 side chain 
observed in all crystal structures (no electron density detected). Compounds bearing a 
lipophilic piperidine 4-substituent (16b, 16c, and 16e) displayed moderate cell permeability 
(Caco-2 assay, A to B flux) similar to that of 16a (Table 1). However, the introduction of a 
heteroaromatic ring (16h and 16i), or the inclusion of an additional basic centre (16j, 16l, and 
16m) had a detrimental effect on cell permeability (Table 1).  
Table 2.  4-Phenylpiperidine  derivatisation: p-Phenyl substitutiona  
                                              
Compound 
 
         X KDM4A 
IC50 (µM) 
KDM4B 
IC50 (µM) 
KDM5B 
IC50 (µM) 
KDM5C 
IC50 (µM) 
Caco-2 
(x10-6 
cm/s) 
17a 
 
0.218 0.153 0.146 
 
0.896b not 
tested 
17b 
 
0.131 
 
0.024± 
0.018 
0.080 0.246 2.29 
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17c 
 
0.068 0.032 0.127b 0.549b <1.81 
17d 
 
0.188± 
0.063 
0.079± 
0.033 
 
0.081b 
 
0.313b 
not 
tested 
17e 
 
0.077± 
0.007 
0.018± 
0.006 
0.026b 0.053b <0.55 
17f 
 
0.093 0.020± 
0.011 
0.012 
 
0.048 
 
<0.76 
17g 
 
0.103 
 
0.020± 
0.009 
0.041 0.108 <1.52 
aResults are mean values of two independent determinations or mean (±SD) for n>2 unless 
specified otherwise. bResults are from a single experiment. 
 
We subsequently investigated the effect of selected p-substituents on the 4-phenylpiperidine 
moiety. The presence of a 6-membered heterocycle (17a-c, Table 2) or alkyl chains bearing a 
basic centre (17e and 17f, Table 2) elicited a KDM4/5 inhibitory profile similar to their m-
substituted counterparts with no evidence of clear selective KDM4 over KDM5 inhibition 
(Tables 1 and 2). However, selectivity for dual KDM4/5 inhibition over other KDM 
subfamilies was maintained; for example 17f displayed a weaker inhibitory activity against 
KDM2A (IC50 = 1.42 µM), KDM3A (IC50 = 2.02 µM), and KDM6B (IC50 = 52.41 µM). 
Crystal structures of 17b, 17e and 17f bound to KDM4A confirmed that the phenyl p-
substituent points towards the solvent accessible region without making any specific contact 
with the protein including the targeted residue E169 (Figure 5). More precisely, the p-
substituents of both 17b and 17e could not be associated with any electron density, 
suggesting high mobility and lack of stabilisation by the protein. In the 17f-bound KDM4A 
structure, the p-dimethylamino moiety points towards the solvent accessible region, but 
without clear interactions with the protein (Figure 5). Similarly to the m-substituted 
analogues (Table 1), p-substituted compounds displayed significantly lower permeability in 
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the Caco-2 assay (A to B flux) relative to that of 16a (Table 2). This drop in cellular 
permeability is consistent with increased polarity and/or the presence of a basic nitrogen.  
 
Figure 5: Overlay of crystal structures of 17b (pink), 17e (magenta) and 17f (light-green) 
bound to KDM4A. Zn(II) atoms are shown as grey spheres. Protein backbone chains are 
represented as cartoon tubes, key residues are displayed in line representation. The pyridyl 
ring in 17b has not been modelled due to too weak density of the corresponding atoms. 
Compounds 17b, 17e and 17f are shown in ball and stick representation. 
Table 3. 4-Phenylpiperidine derivatisation: 3,5-phenyl substitutiona  
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Compou
nd 
 
  X         Y KDM4A 
IC50 (µM) 
KDM4B 
IC50 (µM) 
KDM5B 
IC50 (µM) 
KDM5C 
IC50 (µM) 
Caco-2 
(x10-6 
cm/s) 
18ab 
 
 
CF3 
         
        H 
 
0.128 
 
0.039 
 
0.018 
 
0.070 
 
15.31 
18b 
 
 
CF3 
 
 
0.071 
 
0.033± 
0.015 
 
0.017 
 
0.038 
 
 
<0.76 
18c 
 
 
CF3 
 
 
0.246± 
0.146 
 
0.102± 
0.062 
 
0.032c 
 
0.096c 
 
<0.76 
aResults are mean values of two independent determinations or mean (±SD) for n>2 unless 
specified otherwise. bData taken from reference 29. cResults are from a single experiment.   
 
Noting that both m-chloro, -fluoro, -trifluoromethyl [29] substituents, and alkyl chains 
bearing basic centres at the m-position of the distal phenyl ring (Table 1) impart potent and 
balanced KDM4/5 subfamily inhibition, and also that their binding modes are potentially 
complementary (see overlay of 16a and 16m, Figure 4), we combined these two substituents 
in a small series of 3,5-disubstituted phenyl derivatives (Table 3). Synthesis of the most 
desired compounds with both m-Cl and m-alkylamino side chains proved challenging due to 
competing dehalogenation upon reduction of the piperidine double bond (Scheme 2). 
Nevertheless, we were able to combine a m-CF3 substituent with basic functionality in the 
remaining m-position (18b,c; Table 3). This approach led to potent dual KDM4 and KDM5 
inhibition but no additive inhibitory effect was observed (Table 3), and the KDM4/5 
inhibitory profile was broadly similar to that observed with the corresponding mono-
substituted analogues (Tables 1 and 3). We subsequently solved the structure of 18a bound to 
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KDM4A (Figure 6). This structure indicated that the pendant phenyl ring is rotated such that 
the m-CF3 substituent does not form an interaction with V313 in contrast to its m-Cl 
counterpart (compare Figures 2, 4 and 6). This observation could partly explain the lack of 
additive SAR in compounds 18b and 18c, assuming that the m-CF3 substituent in these 3,5-
disubstituted phenyl derivatives occupies the same position as observed for 18a. Compounds 
18b and 18c maintained a selective inhibition profile versus other KDM subfamily members; 
for example, 18b displayed weaker inhibitory activity against KDM2A (IC50 = 3.77 µM), 
KDM3A (IC50 = 5.68 µM), and KDM6B (IC50 = 23.97 µM). However, both 18b and 18c 
displayed low Caco-2 permeability (A to B flux) in line with previous results obtained with 
compounds bearing a basic substituent on the phenyl ring (Table 1 and 2). 
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Figure 6: Overlay of crystal structures of 18a (brown) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as grey spheres. Proteins backbone chains are represented as cartoon 
tubes, key residues are displayed in line representation. Compounds 18a and 16a are shown 
in ball and stick representation. 
 
 
 
Table 4. Pyrazole C4-substituent: Conformational restrictiona                        
                                               
Compound 
 
               
             R 
KDM4A 
IC50 (µM) 
KDM4B 
IC50 (µM) 
KDM5B 
IC50 (µM) 
KDM5C 
IC50 
(µM) 
Caco-2 
(x10-6 
cm/s) 
19a 
 
   
 
0.100± 
0.041 
 
0.043± 
0.021 
 
0.038 
 
 
0.123 
 
11.64 
19b 
 
 
  
 
 
 
0.143± 
0.056 
 
 
0.045 
 
 
0.114 
 
 
 
 
0.214 
 
 
18.06 
19c 
 
 
 
0.184± 
0.069 
 
0.057 
 
0.123b 
 
 
0.470b 
 
4.25 
19d 
 
 
 
0.107± 
0.020 
 
0.029± 
0.006 
 
0.014b 
 
not 
tested 
 
13.33 
aResults are mean values of two independent determinations or mean (±SD) for n>2 unless 
specified otherwise. bResults are from a single experiment.  
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We next turned our attention to constraining the C4-pyrazole substituent in order to maintain 
contact with V313 whilst minimising the entropic cost associated with ligand binding. We 
envisaged that the lipophilic contact with V313 (KDM4A) (Figure 2) could be optimised by 
conformational restriction directing the phenyl ring towards V313. This hypothesis led to 
synthesis of the spirocyclic analogue 19a which inhibited KDM4 and KDM5 subfamily 
members with IC50 values similar to those observed with 16a (Tables 1 and 4). 19a also 
displayed selective inhibition of KDM4/5 over other KDM subfamilies, inhibiting KDM2A, 
KDM3A, and KDM6B with IC50 values of 4.50, 5.78 and 90.22 µM, respectively. 
 
Figure 7: Overlay of crystal structures of 19a (grey) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, 
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key residues are displayed in line representation. Compounds 19a and 16a are shown in ball 
and stick representation. 
The crystal structure of 19a bound to KDM4A (Figure 7) revealed a binding mode similar to 
that of 16a, with the phenyl ring of the spirocyclic system slightly closer to the side chain of 
V313 than in 16a (closest phenyl carbon atom is 3.7Å from the side chain of V313 for 19a, 
versus 4Å for the corresponding carbon in 16a). In the 19a-bound KDM4A crystal structure, 
we also observed that a loop comprising KDM4A residues 308-313 folds over the 
conformationally restricted spirocyclic phenyl ring to elicit favourable hydrophobic stacking 
interactions with both Cα and Cβ atoms of D311. In addition, we also observed electron 
density for the main chain and Cβ of E169 below the spirocyclic phenyl ring of 19a − 
interestingly, E169 is not commonly visible due to both main chain and side chain flexibility. 
Further, the pyrazole C4-substituent in 19a is associated with a stronger electron density than 
for the corresponding 16a structure, and is well defined in all four chains of the asymmetric 
unit with B factors significantly lower than for the corresponding atoms in 16a (average B 
factors of the terminal phenyl in 19a is 0.8 times the average B factor for the whole structure, 
while it was 1.3 times for 16a). These observations suggest that 19a is more stably bound in 
the active site of KDM4A than 16a. Compounds 19b and 19c gave no improvement to 
KDM4/5 inhibitory profiles relative to 19a (Table 4); however, comparison of the structures 
of 19a and 16a bound to KDM4A (Figure 7) prompted us to introduce a methyl group at the 
piperidine C4-position in 16a to restrict the conformation without a spirocyclic ring system. 
Pleasingly, 19d (Table 4) exhibited a KDM4/5 inhibitory profile similar to that observed with 
19a and the crystal structure of 19d bound to KDM4A revealed the m-Cl phenyl substituent 
in an equatorial position with the Cl atom making contact with V313 (distance of 3.5 Å, 
Figure 8). However, the pyrazole C4-substituent appeared less well stabilised than its 
equivalent in 19a (the full substituent is seen only in one chain for 19d, and with B factors up 
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to 1.3 times higher than the average of the structure). This may arise from freedom of rotation 
around the piperidine C4-bond in 19d and 16a compared to the constrained spirocyclic 
compound 19a. Satisfyingly, all analogues in this subseries displayed good permeability in 
the Caco-2 assay (A to B flux; Table 4).  
 
Figure 8: Overlay of crystal structures of 19d (pink) and 16a (beige) bound to KDM4A. 
Zn(II) are shown as spheres. Proteins backbone chains are represented as a cartoon tubes, key 
residues are displayed in line representation. Compounds 19d and 16a are shown in ball and 
stick representation. 
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Table 5. Pyrazole C4-substituent: Conformational restrictiona 
                                                        
Compound 
 
        R KDM4A 
IC50 (µM) 
KDM4B 
IC50 (µM) 
KDM5B 
IC50 (µM) 
KDM5C 
IC50 (µM) 
Caco-2 
(x10-6 
cm/s) 
34a 
 
       Me 2.06 0.82 0.156 0.163 <0.76 
34b        Et 0.693± 
0.231 
0.455± 
0.037 
0.149 
 
0.081b <0.76 
34c 
     
0.848± 
0.234 
0.504± 
0.072 
0.439 0.566 
 
not 
tested 
34d 
  
 
1.06 
 
0.497 
 
0.601b 
 
0.856b 
not 
tested 
 
34e 
 
 
0.756 
 
0.372 
 
0.447b 
 
0.571b 
 
<0.76 
 
34f 
 
 
0.559± 
0.152 
 
0.248± 
0.048 
 
0.134 
 
0.202b 
 
5.46 
34g 
 
0.613 0.302 0.068b 0.132b 2.12 
 
34h 
 
 
2.41 
 
0.573 
 
0.131b 
 
 
0.377b 
 
not 
tested 
aResults are mean values of two independent determinations or mean (±SD) for n>2 unless 
specified otherwise. bResults are from a single experiment.  
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Figure 9: Overlay of crystal structures of 34a (blue) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, 
key residues are displayed in line representation. Compounds 34a and 16a are shown in ball 
and stick representation. 
In a further attempt to restrict the conformation of the C4-pyrazole substituent, we directly 
attached the N-methylpiperidin-4-yl moiety to C4 of the pyrazole to give 34a, a more potent 
inhibitor of KDM5 relative to KDM4 subfamily enzymes by at least 5-fold (Table 5). A 
crystal structure of 34a in complex with KDM4A (Figure 9) revealed electron density for the 
pyrazole substituent in all four chains of the asymmetric unit, with the piperidine nitrogen 
closer to the side chain carboxylate of D191 than with 16a (2.9 Å versus 4.5 Å for 16a). In 
contrast to the 16a-KDM4A structure, the loop comprising residues 160-171 remained in the 
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conformation observed in the apoprotein  structure and no movement was observed for Y175. 
Interestingly, in the 34a-bound structure, the piperidine N-Me is located in close proximity to 
V313 (Figure 9). In an attempt to further understand the KDM5B-preferring activity of 34a 
(Table 5), we also solved the crystal structure of 34a bound to KDM5B (Figure S5). Given 
the higher potency of 34a against KDM5B relative to KDM4A, we were surprised to find that 
the electron density corresponding to the C4-pyrazole substituent was less well resolved in 
the 34a-KDM5B structure, with no interpretable density for the piperidine N-Me group 
(Figure S5). Furthermore, no interaction was observed with the carboxylic acid of residue 
D502 (D191 in KDM4A). Analogous to the 34a-KDM4A structure, residue W486 in 
KDM5B (Y175 in KDM4A) and surrounding loops adopt the Apo conformation (Figure 3 
and Figure S5). However, the piperidine ring of 34a makes a hydrophobic interaction with 
W486 in KDM5B but does not form productive interactions with the equivalent Y175 residue 
in the 34a-KDM4A crystal structure − this may account for the KDM5B-preferring activity 
profile of 34a.  
Recognising the KDM5B-preferring inhibitory profile of 34a (Table 5), the close proximity 
of the N-Me group of 34a to V313, V171 and I168 in KDM4A (Figure 9) prompted us to 
introduce bulkier N-alkyl substituents to improve lipophilic contact with these residues, 
aiming for an enhancement in KDM4 potency. This hypothesis led to the synthesis of 
compounds 34b-h (Table 5); however, most of these analogues displayed only a modest gain 
in KDM4 inhibitory activity relative to 34a, with KDM5 inhibition also maintained (Table 5). 
Weaker inhibition of the other KDM subfamilies was observed; for example, 34f displayed 
inhibition of KDM2A (IC50 = 12.54 µM), KDM3A (IC50 = 6.13 µM), and KDM6B (<60% 
inhibition at 100 µM). 
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Figure 10: A: Overlay of crystal structures of 34a (blue) and 34b (green) bound to KDM4A. 
Chains A and B of the asymmetric unit are shown for 34b-KDM4A structure, as they do not 
show exactly the same conformation for the ligand and its neighbouring protein residues. B: 
Overlay of crystal structures of 34a (blue) and 34g (pink) bound to KDM4A. Chains B and D 
of the asymmetric unit are shown for 34g-KDM4A structure, as they do not show exactly the 
same conformation of the protein. Zn(II) atoms are shown as grey spheres. Protein backbone 
chains are represented as cartoon tubes, key residues are displayed in line representation. 
Compounds are shown in ball and stick representation. The distal methyl group in 34b has 
not been modelled due to too weak density linked to the high mobility of the corresponding 
atoms.  
In an attempt to rationalise the KDM4/5 structure activity relationship (SAR) observations in 
this subseries, we determined the crystal structures of 34b and 34g in complex with KDM4A 
(Figures 10A and 10B, respectively). In both cases, the C4-pyrazole substituent is shifted 
from the position observed in the 34a-bound KDM4A structure and the interaction between 
the piperidine nitrogen and D191 is no longer present. Notably, the pyrazole C4-substituents 
of both 34b and 34g are closer to Y175 and we observe both apo and ligand-induced shifts in 
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the positions of Y175 and nearby loop 161-170. The terminal carbon of the N-ethyl 
substituent of 34b is not associated with any electron density in the four chains of the 
asymmetric unit, and the N-cyclopentane substituent in 34g is seen in only two chains; 
furthermore, interaction with the three targeted residues V313, V171 and I168 is not 
observed. Thus, a piperidine N-substituent bigger than the methyl is sufficient to disrupt the 
interaction with D191, likely because of steric clashes with the side chain of V313 or the 
main chain carbonyl of E169 (both of which lie in close proximity to the N-Me of 34a, Figure 
9). These factors may explain the modest potency improvement for compounds 34b-h 
compared to 34a. We also solved the structures of 34f and 34g bound to KDM5B, which 
were nearly identical to the KDM5B-34a structure (Figure S6), with the exception of an extra 
carbon seen for the piperidine N-substituent of 34f. These structures indicate that the 
piperidine N-substituents of 34f and 34g are mobile, and not making specific interactions 
with the protein, which likely explains the relatively flat SAR for this series of compounds 
against KDM5B. Based on the above observations, this subseries was not pursued further. 
Overall, our investigations towards selective KDM4 over KDM5 inhibition by targeting 
residue differences between the histone substrate binding sites afforded potent dual inhibitors 
of both KDM4 and KDM5 subfamilies in biochemical assays with selectivity versus 
KDM2A, KDM3A, and KDM6B exemplars of other histone demethylase subfamilies. We 
have previously reported the KDM cellular profiling of 16a, and that the KDM inhibitory 
activity of 16a is dependent upon the 2OG co-substrate concentration in a biochemical assay 
[38]. We therefore assessed the 2OG-dependence of KDM inhibitory activity for exemplar 
compounds 16m (Figure S7), 19a (Figure 11), and 34f (Figure S7). For 19a, we observe a 
147-fold drop in KDM4A inhibition with increasing 2OG concentration from 0.25 µM to a 
physiologically relevant concentration of 1mM (Figure 11) [[39], [40], [41]]. Calculated Ki 
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values [42] (Table 6) demonstrate similar affinity for KDM4A and KDM5B (16a, Ki = 0.003 
and 0.002 µM, respectively; 19a, Ki = 0.004 and 0.007 µM, respectively).  
 
Figure 11: 2OG co-substrate competition studies for 19a in KDM4A, KDM4B and KDM5B 
biochemical assays. 
Table 6: KDM4A and KDM5B Ki values; KDM4A/B and KDM5B target engagement in 
cells (InCELL Hunter™ and IF assays)a 
Compd 
          Ki, (µM)            KDM4, EC50 (µM)    KDM5B, EC50 (µM) 
 KDM4A KDM5B KDM4B, 
InCELL 
 Hunter™ 
KDM4A, 
IF assay 
InCELL 
Hunter™ 
IF assay 
16a 0.003 0.002 1.0±0.7 8.5±6.1 0.6±0.2 24.2±16.4 
16b 0.004 0.003 2.0±0.2 not tested 2.9±1.0 not tested 
16h 0.003 0.001 1.4±0.2 10.4b 1.1±0.3 26.0b 
16m 0.002 0.001 3.0±1.6 30.3±23.8 1.4±0.3 3.77b 
17f 0.004 0.004 3.5±0.6 not tested 1.9±0.6 not tested 
19a 0.004 0.007 1.3±0.3 4.7±3.6 4.0±3.5 13.4±8.5 
19d 0.005 0.002 1.7±0.6 5.9b 1.1±0.5 20.8b 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
32 
 
34f 0.026 0.016 9.1±2.3 38% at 200µM 6.6±5.0 26.4±4.4 
aEC50 data are mean values of at least two independent determinations unless specified 
otherwise. bResults from a single experiment.  
In addition to co-substrate competition, the translation of biochemical inhibitory activity into 
cellular target engagement can also be influenced by compound cell permeability and 
residence time. Furthermore, biochemical KDM-subfamily selectivity trends may not be 
maintained in a cellular environment due to differences in the affinity of KDM subfamilies 
for 2OG [[28], [34]], and differences in the KDM expression levels in cells [28]. We 
therefore investigated the cellular target engagement of selected compounds against KDM4A, 
KDM4B, and KDM5B using two orthogonal assay formats. Firstly, an InCELL Hunter™ 
assay based upon measuring compound-mediated protein stabilisation [43]; secondly, a 
previously reported immunofluorescence-based (IF) assay whereby cellular KDM4A and 
KDM5B inhibition is determined by monitoring the levels of H3K9Me3 and H3K4Me3 
histone marks, respectively [38]. Testing of the known selective KDM5-subfamily inhibitor 6 
in both the InCELL Hunter™ and IF assays provided KDM5B EC50 values of 0.3 and 0.6 
µM, respectively, entirely consistent with previously reported KDM5 EC50 value of 0.34 µM, 
based on assessment of H3K4Me3 levels in PC9 cells [31].  
We initially tested compounds in the InCELL Hunter™ assay for KDM4B and KDM5B 
cellular target engagement with several compounds demonstrating EC50 values close to 1 µM 
(Table 6). Interestingly, compounds 16h, 16m and 17f (Tables 1 and 2), that display low 
permeability in the Caco-2 assay, showed cellular target engagement suggesting cellular 
internalisation under the assay conditions. We also profiled compounds in the cellular IF 
assay (Table 6). Both 19a and 19d inhibited KDM4A demethylase activity in cells (EC50 = 
4.7 and 5.9 µM, respectively), slightly more potently in comparison to KDM5B inhibition 
(EC50 = 13.4 and 20.8 µM, respectively; Table 6). Consistent with our in vitro biochemical 
2OG competition experiments, we observe a 1175-fold drop in KDM4A biochemical potency 
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to IF cell-based activity for 19a, a trend that is replicated across all compounds tested (Table 
6). Of note, the cellular KDM4A and KDM4B EC50 values for 19a (Table 6) are similar to 
the KDM4A and KDM4B biochemical IC50 values obtained at a physiologically relevant 
2OG concentration (approximately 1 mM) [[39], [40], [41]] (IC50 = 2.21 µM, and 0.79 µM, 
respectively, Figure 11). As a further confirmation of cell-based activity, 19a was tested in 
the IF assay alongside its matched pair inactive control 41 (KDM4A, KDM4B and KDM5B 
in vitro biochemical IC50 > 15µM) (Scheme 6, Figure 12). In this assay format, we created an 
assay window through overexpression of the catalytically active protein since were unable to 
measure changes in endogenous methyl marks. The mutant protein used in the assay is 
catalytically dead; as such, addition of an inhibitor should have no effect on the methyl marks 
providing that no modulation of endogenous methyl marks occurs. Pleasingly, compound 41 
did not alter levels of H3K9Me3 nor H3K4Me3 histone methyl marks (Figure 12) suggesting 
that elevation of these marks upon incubation of the cells with 19a is due to cell-based 
inhibition of KDM4 or KDM5 subfamily enzymes by compound 19a. 
Taken together, these studies suggest that the 2-OG competitive inhibition mode of the C8-
substituted pyrido[3,4-d]pyrimidin-4(3H)-one series is the major contributing factor to the 
drop off between in vitro biochemical and cell-based potency, and that a greater than 10-fold  
improvement in biochemical KDM4 inhibitory activity would likely be required to achieve 
sub-micromolar cellular KDM4 inhibition. In addition, if the observed tentative selectivity 
trends regarding cellular target inhibition are maintained, then a 10-fold KDM4 over KDM5 
in vitro biochemical selectivity window may be sufficient to provide a 30-fold KDM4 
selective inhibitor in cells.  
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Figure 12: KDM4A and KDM5B target engagement in HeLa cells by 19a and its matched 
pair inactive control 41 based on modulation of the relevant histone methyl mark (IF assay). 
Constructs encoding FLAG-tagged wild type KDM4A or catalytically inactive mutant 
(H188A/E190A) KDM4A, and wild type KDM5B or catalytically inactive mutant 
(H499A/E501A) KDM5B were used. 
We have previously reported that aldehyde oxidase (AO)-mediated metabolism at C2 of the 
pyridopyrimidinone scaffold leads to high in vivo clearance for this class of compounds, 
precluding their use in in vivo settings [44]. Given these findings, we investigated the stability 
of the pyridopyrimidinone derivatives in cellular cultures in vitro, and found no evidence of 
cell-based metabolism. For example, incubation of 19a and its inactive control 41 in human 
prostate carcinoma LNCaP cells for up to 120 h showed uptake of the parent compounds in a 
time-dependent manner and stable concentrations in media with no metabolites detected in 
cells or media culture. We further characterised 19a by measuring its kinetic aqueous 
solubility (93.3 µM), human plasma protein binding (89%), and in vitro intrinsic microsomal 
clearance in mouse, rat, and human (7.5, 19.8, and 24.7 µL/min/mg, respectively). 
4. Conclusion 
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Following our discovery of C8-pyridopyrimidinone-based analogues 4 and 16a as selective, 
dual KDM4 and KDM5 subfamily inhibitors [29], we determined the crystal structures of 16a 
in complex with both KDM4A and KDM5B. Both structures reveal that the C8-substituent 
extends towards the histone substrate binding site and the solvent exposed surface of the 
enzymes. We identified residues in close proximity to the m-Cl phenyl moiety of 16a that are 
conserved within, but differ between the KDM4 and KDM5 subfamilies. Targeting these 
residues, in particular E169 and V313 (KDM4A numbering), did not elicit the desired KDM4 
over KDM5 selectivity profile in in vitro biochemical assays; likely due to mobility of the 
histone peptide binding region of both the KDM4A and KDM5B proteins, and 
conformational flexibility of the synthesised ligands. Nevertheless, many compounds 
displayed a potent and selective KDM4/KDM5 dual inhibition. Conformational constraint of 
the pyrazole C4-substituent by direct attachment of an N-methylpiperidin-4-yl moiety 
provided 34a, a KDM5-subfamily preferring inhibitor. Subsequent structure-based design to 
increase KDM4 potency for this subseries via optimising lipophilic interactions with V313 
(KDM4A numbering) proved unsuccessful. In an alternative approach, we rigidified the 
distal part of the flexible pyrazole C4-substituent, and optimised interactions with V313 by 
introducing a spirocyclic ring system which led to 19a, a potent, cell-penetrant and selective 
KDM4/KDM5 dual inhibitor. A crystal structure of 19a bound to KDM4A confirmed a 
binding mode broadly similar to that of 16a and revealed distinct features including an 
induced-fit movement of loop 308-313 of KDM4A which folds over the phenyl ring of the 
spirocyclic system to create a hydrophobic stacking interaction with both the main chain and 
Cβ of D311. Compound cellular profiling in two orthogonal target-engagement assays 
revealed a significant drop from biochemical to cell-based activity across multiple analogues. 
Compounds 19a and 19d showed single digit µM KDM4A/KDM4B cellular inhibitory 
activity in the two orthogonal cell-based assay formats. Detailed characterisation of 19a and 
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additional analogues suggests that the significant drop in potency from in vitro biochemical 
to cell-based target engagement assays can be mainly attributed to the 2OG-competitive 
mode of inhibition. Taken together, our data suggests that sub-1nM in vitro biochemical 
affinity will be required with this C8-substituted pyridopyrimidinone series in order to 
achieve sub-µM target inhibition in cells. Achieving sub-1nM KDM4 biochemical potency, 
together with KDM5-subfamily selectivity via pyridopyrimidinone C8-derivatisation, is 
likely to be challenging. The lessons learned may be applied to a different scaffold to achieve 
potent and selective KDM4 inhibition. 
5. Experimental Section 
KDM4A and KDM4B AlphaScreen™ biochemical assays. KDM4A and KDM4B IC50 
values were determined as previously described [29]. In these assays 2OG co-substrate 
concentrations were as follows: KDM4A: 10 µM; KDM4B 2 µM.  
KDM5B and KDM5C AlphaScreen™ biochemical assays: KDM5B and KDM5C IC50 
values were determined as previously described [29]. In these assays 2OG co-substrate 
concentrations were as follows: KDM5B: 5 µM; KDM5C: 5 µM.  
KDM2A, KDM3A and KDM6B AlphaScreen™ biochemical assays. IC50 values were 
determined as previously described [29] and references cited therein. In these assays 2OG co-
substrate concentrations were as follows: KDM2A: 10 µM; KDM3A: 5 µM; KDM6B: 10 
µM. 
Cell-based assays for KDM4A/B and KDM5B target engagement  
IF assay:  Mammalian overexpression constructs encoding full length 1*FLAG-tagged wild 
type, or catalytically inactive mutant (H188A/E190A), KDM4A were obtained from the 
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Structural Genomics Consortium. Constructs encoding wild type or catalytically inactive 
mutant (H499A/E501A) KDM5B have been previously described [38]. 
HeLa cells (ATCC) were routinely cultured at 37°C, 5% CO2 in DMEM (Sigma-Aldrich, 
UK) supplemented with 10% FBS (Gibco, UK), 1% L-glutamine (Gibco, UK) and 1% non-
essential amino acids (Sigma-Aldrich, UK), and passaged regularly using 0.25 % Trypsin-
EDTA (Sigma-Aldrich, UK) before reaching confluence.  
For IF, 6000 cells/well were seeded into a 96-well clear bottom ViewPlate (PerkinElmer, 
UK) and incubated overnight. DNA overexpression vectors were transfected into cells using 
HeLaFect transfection reagent (OZBIOSCIENCES, France). Briefly, 0.1 µg/well plasmid 
DNA and 0.15 µL/well HeLaFect were diluted in separate tubes containing 25 µL/well 
OptiMEM (Gibco, UK). The two solutions were gently mixed in a 1:1 ratio and incubated for 
20 min at room temperature. Following aspiration of the culture medium, the DNA-lipid 
complex was added to cells and incubated for 4 hrs at 37°C, 5% CO2. Compounds were 
prepared in culture medium supplemented with 20% FBS and an appropriate volume of 
DMSO (Sigma-Aldrich, UK) to maintain solvent concentration. Compounds were serially 
diluted at a 1:3 to 1:5 dilution ratio to 5X final concentration in a 96-well plate 
(ThermoFisher Scientific, UK). Compound was then added to cells and incubated for a 
further 24 hrs at 37°C, 5% CO2. After 24 hrs compound incubation, cells were stained for 
immunofluorescence and analysed as previously described.38 Immunofluorescence images of 
10 fields of view per well were captured through a 20X objective on the PerkinElmer IN Cell 
2200 instrument. High-content analysis was performed using INCell Analyzer software (GE 
Healthcare, UK), and concentration-response curves generated in GraphPad Prism 6 
(GraphPad, USA) and Dotmatics (Dotmatics, UK).  
InCELL Hunter™ assay: KDM4B and KDM5B cellular target engagement assays were set 
up using the InCell Hunter Target Engagement Kit from DiscoverX (DiscoverX 2018) [43]. 
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For the KDM4B assay, the expressed protein comprised the N-terminal region of KDM4B 
(aa’s 1-348) fused upstream of the F24 mutant (E31G-R71G-K105E) of FKBP1A [45] with 
an ePL tag (enhanced ProLabel, DiscoverX) appended at the C-terminus. In the KDM5B 
assay, the N-terminal region (aa’s 26-772) of the protein fused with a C-terminal ePL tag was 
used. Constructs were transfected over 24 h in HEK293T cells using Lipofectamine 3000 
(ThermoFisher Scientific). 2.5 x 103 transfected cells / well were re-plated in 384 assay plates 
before treating with compounds over 6 h. To complete the assay, cells were incubated over 
30 min at RT with the InCell Hunter assay reagents mix following the manufacturer’s 
instructions before reading the chemiluminescent signal.  
Crystal structure determinations:  
KDM4A structures. A previously established 6His-TEV-KDM4A construct (residues 
1−359) [46] was produced in Escherichia coli and purified by nickel affinity 
chromatography, followed by tag removal with TEV protease, reverse nickel affinity, and gel 
filtration. The protein was stored at −80 °C at 10 mg/mL in a buffer containing 10 mM 
HEPES pH 7.5 and 200 mM NaCl. Purified KDM4A was crystallized in the apo form at 18 
°C using the hanging-drop vapor-diffusion method. The crystallization drops were composed 
of 1.5 µL of protein (7 mg/mL) and 1.5 µL of reservoir solution containing 14% (w/v) 
PEG4000 and 0.1 M BTP pH 7.5, placed over 800 µL of reservoir solution. Plate-like crystals 
typically grew in a week at 18 0C and were soaked by addition of 0.75 µL of compound at 
50−200 mM in DMSO directly to the drops, followed by 4−48 h incubation at 18 °C. Crystals 
were briefly transferred to cryoprotectant solution containing 14% (w/v) PEG4000, 75 mM 
BTP pH 7.5, and 25% (v/v) glycerol prior to freezing in liquid nitrogen. 
KDM5B structures. A previously established 6His-TEV-KDM5B construct (residues 26-
771∆101−374) [47] was produced in Sf9 cells and purified by nickel affinity 
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chromatography, followed by tag removal with TEV protease, gel filtration and reverse 
nickel affinity. Protein was concentrated to 8 mg/mL crystallized at 4 °C using the sitting 
drop vapor diffusion method. KDM5B was preincubated with 4 mM MnCl2 before the 
protein was transferred to crystallization plates. Crystals were obtained in drops consisting of 
100 nL of protein (8 mg/mL), 200 nL of a precipitant consisting of 1.6 M Na/K phosphate, 
0.1 M HEPES pH 7.5, and 20 nL of KDM5B seeds from crystals obtained from the same 
condition. Crystals were grown at 4 °C, then compounds were soaked into apo crystals for 5 
min at a final concentration of 5 mM. Crystals were cryoprotected with mother liquor 
supplemented with 25% ethylene glycol prior to freezing in liquid nitrogen. 
Data collection, processing and refinement: X-ray data were collected in-house at the 
Institute of Cancer Research, London, UK, on a Rigaku FRX-AFC11-VariMax Cu-VHF-
Pilatus300K, and at Diamond Light Source, Oxfordshire, UK, on beamlines I02, I03, and 
I04-1. Crystals of KDM4A belonged to the space group P 1 21 1 and diffracted to a resolution 
between 2.14 and 2.81 Å. KDM5B crystals belonged to the space group P 65 2 2 and 
diffracted to a resolution between of 2.14 and 2.3 Å. Datasets were integrated with XDS [48] 
and scaled and merged with AIMLESS [49]. Structures were solved by molecular 
replacement using PHASER [[50], [51]] with the publicly available KDM4A and KDM5B 
structures (PDB codes 2OQ7 and 5A1F, respectively) [[46], [47]] with ligand and water 
molecules removed used as molecular replacement models. All protein−ligand structures 
were manually corrected and rebuilt in COOT [52] and refined with BUSTER [53] in iterative 
cycles. Ligand restraints were generated with GRADE [54] and MOGUL [55]. The quality of 
the structures was assessed with MOLPROBITY [[56], [57]]. The data collection and 
refinement statistics are presented in Supporting Information Table S1. 
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Caco-2 permeability: Caco-2 cellular permeability was determined as previously described 
[29].  
Cell uptake experiment and stability of 19a in cellular culture:  
LNCaP cells (ATCC) were routinely cultured at 37 °C, 5 % CO2 in RPMI-1640 (Sigma-
Aldrich, UK) supplemented with 10 % FBS (Gibco, UK), and passaged regularly using 0.25 
% Trypsin-EDTA (Sigma-Aldrich, UK) before reaching confluence.  
For cell uptake and stability experiments, 1.5 x 105 cells/well were seeded into 6-well plates 
(Corning, UK) and incubated for 48 h at 37 °C, 5 % CO2, before treatment with either 10 µM 
compound or 0.1 % DMSO (Sigma-Aldrich, UK) as vehicle control. Following 1, 6, 24, 48, 
72 and 120 h incubation, media was collected from cells and immediately frozen at –80 °C. 
Cells were trypsinised, pelleted and then frozen at –80 °C until analysis.  
Cell and tissue culture media extracts were analysed using a Dionex Ultimate 3000 UHPLC 
system coupled to a Thermo Scientific Q Exactive Plus orbitrap mass spectrometer (Thermo 
Fisher Scientific Inc., Waltham, USA). Separation of analytes was achieved using an Acquity 
UPLC HSS T3 column (1.8 µm, 100 x 2.1 mm) (Waters, Elstree, UK) at a temperature of 
50°C and a binary mobile phase gradient at a flow rate of 0.4 mL/min. Initial LC conditions 
comprised 10% solvent A (0.1% formic acid in water), 90% solvent B (methanol); this was 
ramped to 95% A at 12 min, immediately returned to initial conditions and held for the 
remaining three minutes of the method. Sample analysis was by electrospray atmospheric 
pressure ionization combined with full scan acquisition in positive ion mode. The capillary 
voltage was 3.5 kV; desolvation gas and capillary temperatures were 450°C and 275°C 
respectively; sheath, aux and sweep gas flow rates were 55, 15 and 3 respectively. Full 
MS/dd-MS2 (full MS scan followed by data dependent MS/MS) and Full MS/AIF (full MS 
scan followed by all ion fragmentation) workflows were used in combination. 
Identification/presence of metabolites was undertaken with the aid of the software Compound 
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Discoverer (v2.0.0.303, Thermo Fisher Scientific Inc., Waltham, USA). Raw data files of the 
incubation time course generated in the acquisition software Chromeleon (v7.2 SR3 (7553)), 
Thermo Fisher Scientific Inc., Waltham, USA) were input into the targeted workflow.  
 
Chemistry: Commercially available starting materials, reagents and anhydrous solvents were 
used as supplied. Flash column chromatography was performed using Merck silica gel 60 
(0.025 – 0.04 mm). Thin layer chromatography was performed using Merck Millipore TLC 
silica gel 60 F254 aluminium sheets and visualised by UV (254 & 280 nm), iodine and 
KMnO4. Column chromatography was also performed on a FlashMaster personal unit using 
isolute Flash silica columns or a Biotage Isolera purification system using Biotage KP-SNAP 
cartridges. Ion exchange chromatography was performed using acidic Isolute Flash SCX-II 
cartridges or basic Isolute Flash NH2 cartridges. 1H NMR spectra were recorded on either a 
Bruker Avance-500 or Bruker Avance-400 NMR machine. Samples were prepared as 
solutions in a deuterated solvent and referenced to the appropriate internal non-deuterated 
solvent peak or tetramethylsilane. Chemical shifts were recorded in ppm (δ) downfield of 
tetramethylsilane. 
LC-MS Analysis. Analysis was performed using an Agilent 1200 series HPLC and diode 
array detector coupled to a 6210 time of flight mass spectrometer with dual multimode 
APCI/ESI source.  
Method A: Analytical separation was carried out at 40 °C on a Merck Chromolith Flash 
column (RP-18e, 25 × 2 mm) using a flow rate of 1.5 mL/min in a 2 minute gradient elution 
with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) and water 
(solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 5:95 (A/B) 
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to 100:0 (A/B) over 1.25 min, 100:0 (A/B) for 0.5 min, and then reversion back to 5:95 (A/B) 
over 0.05 min, finally 5:95 (A/B) for 0.2 min. 
 Method B: Analytical separation was carried out at 30 °C on a Merck Chromolith Flash 
column (RP-18e, 25 x 2 mm) using a flow rate of 0.75 mL/min in a 4 minute gradient elution 
with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) and water 
(solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 5:95 (A/B) 
to 100:0 (A/B) over 2.5 min, 100:0 (A/B) for 1 min, and then reversion back to 5:95 (A/B) 
over 0.1 min, finally 5:95 (A/B) for 0.4 min. 
Analysis was also performed on a Waters Acquity UPLC and diode array detector coupled to 
a Waters G2 QToF mass spectrometer fitted with a multimode ESI/APCI source.  
Method C: Analytical separation was carried out at 30 °C on a Phenomenex Kinetex C18 
column (30 × 2.1 mm, 2.6u, 100A) using a flow rate of 0.5 mL/min in a 2 minute gradient 
elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) 
and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 
10:90 (A/B) to 90:10 (A/B) over 1.25 min, 90:10 (A/B) for 0.5 min, and then reversion back 
to 10:90 (A/B) over 0.15 min, finally 10:90 (A/B) for 0.1 min. 
Method D: Analytical separation was carried out at 30°C on a Phenomenex Kinetex C18 
column (30 × 2.1 mm, 2.6u, 100A) using a flow rate of 0.3 mL/min in a 4 minute gradient 
elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) 
and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 
10:90 (A/B) to 90:10 (A/B) over 3 min, 90:10 (A/B) for 0.5 min, and then reversion back to 
10:90 (A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min. 
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Analysis was also performed on a Waters system equipped with a Waters 2545 binary 
gradient module, a Waters SQ Detector 2, Waters 2489 UV/visible detector, and a Waters 
2424 ELS detector. 
 Method E: Analytical separation was carried out on a Kinetex 5u EVO C18 column (100 
mm × 3.0 mm, 100 A) using a flow rate of 2 mL/min in a 3 min gradient elution. The mobile 
phase was a mixture of 93% H2O, 5% acetonitrile, and 2% of 0.5 M ammonium acetate 
adjusted to pH 6 with glacial acetic acid (solvent A) and 18% H2O, 80% acetonitrile, and 2% 
of 0.5 M ammonium acetate adjusted to pH 6 with glacial acetic acid (solvent B). Gradient 
elution was as follows: 95:5 (A/B) 0.35 min, 95:5 (A/B) to 5:95 (A/B) over 1 min, 5:95 (A/B) 
over 0.75 min, and then reversion back to 95:5 (A/B) over 0.1 min and 95:5 (A/B) over 0.8 
min. 
LC-HRMS analysis was performed using either an gilent 1200 series HPLC and diode 
array detector coupled to a 6210 time of flight mass spectrometer with dual multimode 
APCI/ESI source (method B) or a Waters Acquity UPLC and diode array detector coupled to 
a Waters G2 QToF mass spectrometer fitted with a multimode ESI/APCI source (method D). 
LC-HRMS method B referenced to caffeine [M+H]+ 195.087652 or hexakis (2,2-
difluroethoxy)phosphazene [M+H]+ 622.02896 or hexakis(1H,1H,3H-
tetrafluoropentoxy)phosphazene [M+H]+ 922.009798. LC-HRMS method D referenced to 
Leucine Enkephalin fragment ion [M+H]+ 397.1876.  
Preparative HPLC (for the purification of 34a) purification was carried out using a Merck 
Chromolith column (RP18-e 10 x 100 mm) at ambient temperature using a gradient program; 
detection was by UV–MS; the flow rate was 10 mL/min. The mobile phase used was A: 
acetonitrile/water = 5/95 with 0.1% NH4HCO3, B: acetonitrile/water = 80/20 with 0.1% 
NH4HCO3. 
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General Procedure 1 – Suzuki coupling: The boronic acid pinacol ester (1 equiv.), aryl 
halide (1 equiv.) and Pd(dppf)Cl2.CH2Cl2 adduct (0.1 equiv.) were dissolved in a mixture of 
DME and aqueous sodium carbonate (1 M) in a microwave vial. The vial was sealed, 
evacuated and backfilled with N2. The reaction mixture was heated in the microwave at 
120 °C for 45 min and monitored by LCMS. The reaction mixture was concentrated in vacuo 
to give the crude material which was purified by Biotage column chromatography (see 
individual compounds for details of the eluent used). 
General Procedure 2 – Dihydropyridine hydrogenation and Boc deprotection: Pd(OH)2 
on carbon (0.4 equiv.) was added to a solution of dihydropyridine (1 equiv.) in EtOH and 
hydrochloric acid (1 M) under an atmosphere of N2. The reaction mixture was then flushed 
with H2 and stirred at room temperature under an atmosphere of H2 (2 atm) for 1 h. The 
reaction mixture was monitored by LCMS. On completion of the reduction, the reaction 
mixture was filtered through celite to remove catalyst and concentrated in vacuo to obtain the 
crude product. The crude material was taken up in THF and hydrochloric acid (1 M), stirred 
at 50 °C for 2 h and monitored by LCMS. On completion of the reaction, the reaction mixture 
was concentrated in vacuo and the residue redissolved in MeOH/ CH2Cl2. The crude material 
was passed through an SCX-2 cartridge eluting with 1 M NH3 in MeOH/CH2Cl2. The 
ammoniacal solution was concentrated in vacuo to yield the product. 
General Procedure 3 – Amine displacement of mesylate using trimethylamine: 
Triethylamine (2 equiv.) was added to a solution of freshly made (from compound 10) 
mesylate intermediate (1 equiv.) and amine (1.2 equiv.) in anhydrous DMF under N2. The 
reaction mixture was heated at 50 °C for 15 h and monitored by LCMS. When the reaction 
had reached completion, the reaction mixture was diluted in H2O and extracted three times 
with EtOAc. The combined organic layers were washed with saturated LiCl solution, 
saturated brine solution, dried over MgSO4 and concentrated in vacuo to give the crude 
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material which was purified by Biotage column chromatography (see individual compounds 
for details of the eluent used). 
General Procedure 4 – SEM Deprotection with 6 M HCl/THF: Hydrochloric acid (6 M, 
60-90 equiv.) was added to a solution of SEM protected material (1 equiv.) in THF (0.1 M). 
The reaction mixture was stirred at 50 to 60 °C for between 3 and 8 h and monitored by 
LCMS. Following completion of the reaction, the reaction mixture was concentrated in vacuo 
and purified by Biotage column chromatography on a KP-NH snap column unless otherwise 
stated (see individual compounds for details of the eluent used). The product obtained from 
column chromatography was triturated with Et2O to give the pure product. 
General Procedure 5 – Reductive amination:  To a microwave vial was added the required 
aldehyde (1 equiv.) and corresponding amine (1.5 equiv.) and the flask purged with argon. 
Anhydrous 1,2-dichloroethane (4 mL) or dichloromethane was then added, the mixture 
stirred to allow dissolution followed by the addition of sodium triacetoxyborohydride (1.6 
equiv.), the vial was capped and the mixture stirred at room temperature. Once the reaction 
was deemed complete by LCMS analysis, the mixture was directly absorbed onto silica gel 
and purified by flash column chromatography to afford the requisite amine (workup 
procedure A). Alternatively, the mixture was concentrated to afford an amorphous solid and 
passed through a plug of silica eluting with 40% MeOH/CH2Cl2 to afford an oil which was 
used without further purification (workup procedure B). 
General Procedure 6 – SEM deprotection with HCl/1,4-dioxane: To a microwave vial 
was added the SEM protected starting material (1 equiv), 1,4-dioxane (3 mL) and distilled 
water (1 mL) followed by the dropwise addition of HCl in dioxane (4M, 25 equiv.). The vial 
was capped and the mixture stirred at 50 °C until analysis by LCMS indicated complete 
conversion to the product. The mixture was then concentrated and passed through an SCX-2 
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cartridge washing initially with MeOH and then NH3/MeOH. The basic wash was 
concentrated and triturated with Et2O to afford a solid. If necessary the solid was further 
purified by flash column chromatography on a SNAP KP-NH column eluting with 0-40% 
EtOH/CH2Cl2. 
General Procedure 7 – Synthesis of pyrazole-piperidines: 4-(1H-pyrazol-4-yl)piperidine  
(1 equiv.) was dissolved in NMP or DMF over 4 Å mol sieve in an oven-dried flask under a 
flow of N2. Appropriate aldehyde (3-4 equiv.) was added to the solution in one portion and 
the reaction mixture stirred for 10 min - 6 h (see individual compounds for reaction time) at 
room temperature. Sodium triacetoxyborohydride (2-4 equiv.) was then added and the 
reaction mixture was stirred at room temperature under N2 for 2 h and monitored by LCMS. 
On completion of the reaction, the reaction mixture was concentrated in vacuo and the 
residue redissolved in MeOH/CH2Cl2. The crude material was passed through an SCX-2 
cartridge eluting with 1 M NH3 in MeOH/CH2Cl2. The ammoniacal solution was 
concentrated in vacuo to yield the product. 
General Procedure 8 – SNAr displacement: Cesium carbonate (1.5 equiv.) and the requisite 
pyrazole (1.1 equiv.) were added to a microwave vial equipped with a stirrer bar. This was 
sealed, evacuated and flushed with N2. Anhydrous MeCN was added to the vial and the 
reaction mixture stirred for 20 min under N2 at room temperature. The cap was then removed, 
8-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (1 equiv.) 
was added, the vial resealed, evacuated and flushed with N2. The reaction mixture was then 
stirred at reflux for 18 h. Solids were removed by filtration and rinsed with CH2Cl2 three 
times. The filtrate was concentrated in vacuo to give the crude material which was purified by 
Biotage column chromatography (see individual compounds for details of the eluent used). 
tert-Butyl 4-(3-(pyridin-3-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (22h)  
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According to General Procedure 1, tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
5,6-dihydropyridine-1(2H)-carboxylate (300 mg, 0.970 mmol), 3-(3-bromophenyl)pyridine 
(227 mg, 0.970 mmol) and Pd(dppf)Cl2.CH2Cl2 adduct (79 mg, 0.097 mmol) were reacted 
together in DME (3 mL) and aqueous sodium carbonate (1 M, 2 mL). Purification on a KP-
Sil snap cartridge (9% [0.2 M NH3 in MeOH] in CH2Cl2) gave the product as a brown oil 
(324 mg, quant.); 1H NMR (500 MHz, CDCl3) 1.48 (s, 9H), 2.55 (br s, 2H), 3.64 (t, J = 5.3 
Hz, 2H), 4.08 (s, 2H), 6.08 (br s, 1H), 7.33 (dd, J = 7.9, 4.9 Hz, 1H), 7.36-7.45 (m, 3H), 7.53 
(s, 1H), 7.84 (dt, J = 7.9, 1.9 Hz, 1H), 8.57 (dd, J = 4.8, 1.3 Hz, 1H), 8.82 (br d, J = 2.0 Hz, 
1H); LC - MS (method C; ESI, m/z) tR = 1.40 min – 337 [(M+H)+]; HRMS (method D): 
found 337.1917; calculated for C21H25N2O2 (M+H)+ 337.1916. 
3-(3-(Piperidin-4-yl)phenyl)pyridine (25h)  
According to General Procedure 2, Pd(OH)2 on carbon (134 mg, 0.191 mmol) and tert-butyl 
4-(3-(pyridin-3-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (161 mg, 0.479 mmol) 
were reacted together in EtOH (3 mL) and hydrochloric acid (1 M, 1 mL). The crude material 
from this reaction was then stirred in THF (3 mL) and hydrochloric acid (1 M, 3 mL) and 
purified by passing through an SCX-2 cartridge eluting with 1 M NH3 in MeOH/DCM. The 
ammoniacal solution was concentrated in vacuo to yield the product as an off white solid 
(61.6 mg, 54%); 1H NMR (500 MHz, CDCl3) 1.69 (qd, J = 12.4, 3.7 Hz, 2H), 1.87 (br d, J = 
12.7 Hz, 2H), 2.08 (br s, 1H), 2.69 (tt, J = 12.4, 3.7 Hz, 1H), 2.76 (td, J = 12.2, 2.2 Hz, 2H), 
3.20 (br d, J = 12.3 Hz, 2H), 7.24-7.29 (m, 1H), 7.34 (ddd, J = 7.9, 4.9, 0.8 Hz, 1H), 7.39-
7.44 (m, 3H), 7.85 (ddd, J = 7.9, 2.2, 1.7 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 8.83 (dd, J 
= 2.2, 0.8 Hz, 1H); LC - MS (method C; ESI, m/z) tR = 0.46 min – 239 [(M+H)+]; HRMS 
(method D): found 239.1555; calculated for C16H19N2 (M+H)+ 239.1548. 
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8-(4-(2-(4-(3-(Pyridin-3-yl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-
(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (12h)  
According to General Procedure 3, triethylamine (0.03 mL, 0.215 mmol), 2-(1-(4-oxo-3-((2-
(trimethylsilyl)ethoxy)methyl)-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- 
ethyl methanesulfonate (50 mg, 0.107 mmol) and 3-(3-(piperidin-4-yl)phenyl)pyridine (38.4 
mg, 0.161 mmol) were reacted together in anhydrous DMF (1 mL). Purification on a KP-Sil 
snap cartridge (9% [0.2 M NH3 in MeOH] in CH2Cl2) gave the product as a pale yellow oil 
(25.4 mg, 39%); 1H NMR (500 MHz, CDCl3) 0.01 (s, 9H), 0.95-1.01 (m, 2H), 1.86-1.97 (m, 
4H), 2.17-2.26 (m, 2H), 2.59-2.67 (m, 1H), 2.69-2.76 (m, 2H), 2.82-2.89 (m, 2H), 3.19 (br d, 
J = 11.2 Hz, 2H), 3.67-3.72 (m, 2H), 5.46 (s, 2H), 7.29-7.32 (m, 1H), 7.36 (dd, J = 4.7, 0.7 
Hz, 1H), 7.41-7.45 (m, 2H), 7.46 (br s, 1H), 7.81 (br s, 1H), 7.87 (ddd, J = 7.9, 2.2, 1.7 Hz, 
1H), 8.07 (d, J = 5.1 Hz, 1H), 8.31 (s, 1H), 8.57-8.60 (m, 2H), 8.63 (d, J = 5.1 Hz, 1H), 8.84 
(br d, J = 2.5 Hz, 1H); LC - MS (method C; ESI, m/z) tR = 1.14 min – 608 [(M+H)+]; HRMS 
(method D): found 608.3162; calculated for C34H42N7O2Si (M+H)+ 608.3169. 
8-(4-(2-(4-(3-(Pyridin-3-yl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-
d]pyrimidin-4(3H)-one (16h)  
According to General Procedure 4, 8-(4-(2-(4-(3-(pyridin-3-yl)phenyl)piperidin-1-yl)ethyl)-
1H-pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (16 
mg, 0.026 mmol) and hydrochloric acid (6 M, 1 mL) were reacted together in THF (1 mL). 
Purification on a KP-NH snap cartridge (40% EtOH in CH2Cl2) gave the title product as a 
white solid (7.8 mg, 62%); 1H NMR (500 MHz, DMSO-d6) 1.72-1.86 (m, 4H), 2.10 (td, J = 
11.5, 2.5 Hz, 2H), 2.57-2.65 (m, 3H), 2.73 (t, J = 7.3 Hz, 2H), 3.10 (br d, J = 11.5 Hz, 2H), 
7.33 (br d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.47 (ddd, J = 7.9, 4.7, 0.8 Hz, 1H), 
7.53-7.56 (m, 1H), 7.60 (br t, J = 1.6 Hz, 1H), 7.73 (s, 1H), 7.97 (d, J = 5.1 Hz, 1H), 8.08 
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(ddd, J = 7.9, 2.3, 1.6 Hz, 1H), 8.29 (s, 1H), 8.44 (s, 1H), 8.54 (d, J = 5.1 Hz, 1H), 8.56 (dd, J 
= 4.8, 1.6 Hz, 1H), 8.89 (dd, J = 2.3, 0.8 Hz, 1H), 12.80 (br s, 1H); LC - MS (method C; ESI, 
m/z) tR = 0.69 min (purity: 100%) – 478 [(M+H)+]; HRMS (method D): found 478.2373; 
calculated for C28H28N7O (M+H)+ 478.2355.  
tert-Butyl 4-(4-(pyridin-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (23a)  
According to General Procedure 1, tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
5,6-dihydropyridine-1(2H)-carboxylate (300 mg, 0.970 mmol), 2-(4-bromophenyl)pyridine 
(227 mg, 0.970 mmol) and Pd(dppf)Cl2.CH2Cl2 adduct (79 mg, 0.097 mmol) were reacted 
together in DME (3 mL) and aqueous sodium carbonate (1 M, 2 mL). Purification on a KP-
Sil snap cartridge (5% [0.2 M NH3 in MeOH] in CH2Cl2) gave the product as a pale brown 
solid (96 mg, 29%); 1H NMR (500 MHz, CDCl3) 1.50 (s, 9H), 2.57 (br s, 2H), 3.66 (br t, J = 
4.9 Hz, 2H), 4.10 (br s, 2H), 6.13 (br s, 1H), 7.19-7.23 (m, 1H), 7.48 (d, J = 8.3 Hz, 2H), 
7.71-7.74 (m, 2H), 7.96-7.99 (m, 2H), 8.69 (dt, J = 4.9, 1.3 Hz, 1H); LC - MS (method C; 
ESI, m/z) tR = 1.44 min – 337 [(M+H)+]; HRMS (method D): found 337.1916; calculated for 
C21H25N2O2 (M+H)+ 337.1916. 
2-(4-(Piperidin-4-yl)phenyl)pyridine (26a)  
According to General Procedure 2, Pd(OH)2 on carbon (15.2 mg, 0.108 mmol) and tert-butyl 
4-(4-(pyridin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (91 mg, 0.271 mmol) were 
reacted together in EtOH (3 mL) and hydrochloric acid (1 M, 0.5 mL). The crude material 
from this reaction was then stirred in THF (2 mL) and hydrochloric acid (1 M, 2 mL) and 
then purified by passing through an SCX-2 cartridge eluting with 1 M NH3 in MeOH/CH2Cl2. 
The ammoniacal solution was concentrated in vacuo to yield the product as pale yellow oil 
(46.9 mg, 73%); 1H NMR (500 MHz, CDCl3) 1.68 (qd, J = 12.5, 3.8 Hz, 2H), 1.87 (br d, J = 
12.8 Hz, 2H), 1.99 (br s, 1H), 2.68 (tt, J = 12.1, 3.6 Hz, 1H), 2.76 (td, J = 12.1, 2.4 Hz, 2H), 
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3.21 (br d, J = 12.1 Hz, 2H), 7.20 (ddd, J = 6.7, 4.8, 1.9 Hz, 1H), 7.32-7.35 (m, 2H), 7.69-
7.75 (m, 2H), 7.91-7.96 (m, 2H), 8.66-8.69 (m, 1H); LC - MS (method C; ESI, m/z) tR = 0.47 
min – 239 [(M+H)+]; HRMS (method D): found 239.1545; calculated for C16H19N2 (M+H)+ 
239.1548. 
8-(4-(2-(4-(4-(Pyridin-2-yl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-
(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (13a)  
According to General Procedure 3, triethylamine (0.05 mL, 0.367 mmol), 2-(1-(4-oxo-3-((2-
(trimethylsilyl)ethoxy)methyl)-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- 
ethyl methanesulfonate (85 mg, 0.183 mmol) and 2-(4-(piperidin-4-yl)phenyl)pyridine (43.7 
mg, 0.183 mmol) were reacted together in anhydrous DMF (1 mL). Purification on a KP-Sil 
snap cartridge (8% [0.2 M NH3 in MeOH] in CH2Cl2) gave the product as a pale yellow oil 
(65 mg, 58%); 1H NMR (500 MHz, CDCl3) 0.01 (s, 9H), 0.96-1.01 (m, 2H), 1.86-1.98 (m, 
4H), 2.16-2.27 (m, 2H), 2.57-2.66 (m, 1H), 2.70-2.76 (m, 2H), 2.83-2.90 (m, 2H), 3.20 (br d, 
J = 11.1 Hz, 2H), 3.67-3.72 (m, 2H), 5.46 (s, 2H), 7.21 (ddd, J = 6.7, 4.8, 1.6 Hz, 1H), 7.63 
(br d, J = 8.2 Hz, 2H), 7.70-7.76 (m, 2H), 7.82 (s, 1H), 7.94 (d, J = 8.2 Hz, 2H), 8.07 (d, J = 
5.0 Hz, 1H), 8.31 (s, 1H), 8.60 (s, 1H), 8.63 (d, J = 5.0 Hz, 1H), 8.67-8.69 (m, 1H); LC - MS 
(method C; ESI, m/z) tR = 1.17 min – 478 [(M−SEM+H)+]; HRMS (method D): found 
478.2351; calculated for C28H28N7O (M−SEM+H)+ 478.2355. 
8-(4-(2-(4-(4-(Pyridin-2-yl)phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)pyrido[3,4-
d]pyrimidin-4(3H)-one (17a)  
According to general procedure 4, 8-(4-(2-(4-(4-(pyridin-2-yl)phenyl)piperidin-1-yl)ethyl)-
1H-pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one 
(25.4 mg, 0.042 mmol) and hydrochloric acid (6 M, 1 mL) were reacted together in THF (1 
mL). Purification on a KP-NH snap cartridge (40% EtOH in CH2Cl2) gave the title product as 
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a white solid (19.2 mg, 96%); 1H NMR (500 MHz, DMSO-d6) 1.72 (qd, J = 12.3, 3.3 Hz, 
2H), 1.78-1.84 (m, 2H), 2.07-2.14 (m, 2H), 2.54-2.64 (m, 3H), 2.70-2.75 (m, 2H), 3.10 (br d, 
J = 11.0 Hz, 2H), 7.32 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.38 (br d, J = 8.3 Hz, 2H), 7.73 (s, 
1H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.91-7.94 (m, 1H), 7.98 (d, J = 5.1 Hz, 1H), 8.01 (d, J = 
8.3 Hz, 2H), 8.29 (s, 1H), 8.45 (s, 1H), 8.54 (d, J = 5.1 Hz, 1H), 8.63-8.66 (m, 1H), 12.80 (br 
s, 1H); LC - MS (method C; ESI, m/z) tR = 0.72 min (purity: >98%) – 478 [(M+H)+]; HRMS 
(method D): found 478.2356; calculated for C28H28N7O (M+H)+ 478.2355.  
8-(4-(2-(2,3-Dihydrospiro[indene-1,4'-piperidin]-1'-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-
(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one   
According to general procedure 3, triethylamine (0.03 mL, 0.237 mmol), 2-(1-(4-oxo-3-((2-
(trimethylsilyl)ethoxy)methyl)-3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- 
ethyl methanesulfonate (80 mg, 0.172 mmol) and 2,3-dihydrospiro[indene-1,4'-piperidine] 
(38.6 mg, 0.206 mmol) were reacted together in anhydrous DMF (1 mL). Purification on a 
silica column eluting with 3% [7 M NH3 in MeOH] in CH2Cl2 gave the product as a pale 
yellow oil (42 mg, 44%); 1H NMR (500 MHz, CDCl3) 0.02 (s, 9H), 0.96-1.01 (m, 2H), 1.63 
(d, J = 12.4 Hz, 2H),  1.99-2.03 (m, 4H), 2.34 (br s, 2H), 2.78 (br s, 2H), 2.87-2.95 (m, 4H), 
3.09 (br s, 2H), 3.68-3.74 (m, 2H), 5.48 (s, 2H), 7.16 – 7.26 (m, 4H), 7.82 (s, 1H), 8.07 (d, J 
= 5.1 Hz, 1H), 8.32 (s, 1H), 8.61 (s, 1H), 8.64 (d, J = 5.1 Hz, 1H); LC - MS (method C; ESI, 
m/z) tR = 1.25 min – 557 (M+H)+. 
8-(4-(2-(2,3-Dihydrospiro[indene-1,4'-piperidin]-1'-yl)ethyl)-1H-pyrazol-1-
yl)pyrido[3,4-d]pyrimidin-4(3H)-one (19a)    
According to general procedure 4, 8-(4-(2-(2,3-dihydrospiro[indene-1,4'-piperidin]-1'-
yl)ethyl)-1H-pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-
4(3H)-one (42 mg, 0.075 mmol) and hydrochloric acid (6 M, 1 mL) were reacted together in 
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THF (1 mL) for 4 h. Purification was achieved by passing the crude product through an SCX-
2 cartridge eluting first with methanol and then 7N ammonia in methanol. Fractions 
containing the product were combined, concentrated in vacuo, and the residue triturated with 
Et2O. The beige precipitate was obtained by filtration, and dried (31mg, 96%). 1H NMR (500 
MHz, DMSO-d6): 1.48 (d, J = 12.5 Hz, 2H), 1.86 (td, J = 13.2, 4.3 Hz, 2H),  1.98 (t, J = 7.3 
Hz, 2H), 2.31 (br s, 2H), 2.65 – 2.80 (m, 4H), 2.85 (t, J =7.3 Hz, 2H), 2.95-3.06 (m, 2H), 
7.11-7.21 (m, 4H), 7.75 (s, 1H), 7.99 (d, J = 5.1 Hz, 1H), 8.29 (s, 1H), 8.44 (s, 1H), 8.56 (d, J 
= 5.1 Hz, 1H), 12.59 (br s, 1H); HRMS (method D): tR = 1.83 min (purity:100%) – found: 
427.2233; calculated for C25H27N6O (M+H)+ 427.2246. 
1-Ethyl-4-(1H-pyrazol-4-yl)piperidine (32b)  
According to General Procedure 7, 4-(1H-pyrazol-4-yl)piperidine  
(81 mg, 0.536 mmol) and acetaldehyde (0.1 mL, 1.78 mmol) were reacted together in DMF 
(5 mL) for 10 min. Sodium triacetoxyborohydride (454 mg, 2.14 mmol) was then added. On 
completion of the reaction, the reaction mixture was concentrated in vacuo and the residue 
redissolved in MeOH/CH2Cl2. The crude material was passed through an SCX-2 cartridge 
eluting with 1 M NH3 in MeOH/CH2Cl2. The ammoniacal solution was concentrated in vacuo 
to yield the crude product that was used in the next step without further purification. 
8-(4-(1-Ethylpiperidin-4-yl)-1H-pyrazol-1-yl)-3-((2-
(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (33b)  
According to General Procedure 8, 8-chloro-3-(2-trimethylsilylethoxymethyl)pyrido[3,4-
d]pyrimidin-4-one (125 mg, 0.401 mmol), 1-ethyl-4-(1H-pyrazol-4-yl)piperidine (77.4 mg, 
0.432 mmol) and cesium carbonate (211 mg, 0.648 mmol) were reacted together in 
anhydrous MeCN (3 mL). Purification on a KP-Sil snap cartridge (15% [0.2 M NH3 in 
MeOH] in CH2Cl2) gave the product as a pale yellow oil (76.8 mg, 39%); 1H NMR (500 
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MHz, CDCl3) 0.00 (s, 9H), 0.95-1.00 (m, 2H), 1.19 (t, J = 7.4 Hz, 3H), 1.90 (qd, J = 12.3, 2.8 
Hz, 2H), 2.02-2.10 (m, 2H), 2.20 (t, J = 11.3 Hz, 2H), 2.57 (q, J = 7.4 Hz, 2H), 2.63-2.71 (m, 
1H), 3.14 (br d, J = 11.3 Hz, 2H), 3.66-3.71 (m, 2H), 5.46 (s, 2H), 7.79 (s, 1H), 8.06 (d, J = 
5.0 Hz, 1H), 8.30 (s, 1H), 8.54 (s, 1H), 8.61 (d, J = 5.0 Hz, 1H); LC - MS (method C; ESI, 
m/z) tR = 1.12 min – 455 [(M+H)+]; HRMS (method D): found 455.2590; calculated for 
C23H35N6O2Si (M+H)+ 455.2591. 
8-(4-(1-Ethylpiperidin-4-yl)-1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one (34b)  
According to General Procedure 4, 8-[4-(1-ethyl-4-piperidyl)pyrazol-1-yl]-3-(2-
trimethylsilylethoxymethyl)pyrido[3,4-d]pyrimidin-4-one (38.2 mg, 0.084 mmol) and 
hydrochloric acid (6 M, 1 mL) were reacted together in THF (1 mL). Purification on a KP-
NH snap cartridge (40% EtOH in CH2Cl2) gave the title product as a white solid (23.8 mg, 
87%); 1H NMR (500 MHz, DMSO-d6) 1.02 (t, J = 7.2 Hz, 3H), 1.58 (qd, J = 12.3, 3.4 Hz, 
2H), 1.88-1.94 (m, 2H), 1.98 (t, J = 11.6 Hz, 2H), 2.35 (q, J = 7.2 Hz, 2H), 2.51-2.56 (m, 
1H), 2.96 (br d, J = 11.6 Hz, 2H), 7.73 (s, 1H), 7.97 (d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 8.37 (s, 
1H), 8.52 (d, J = 5.0 Hz, 1H), 12.70 (br s, 1H); LC - MS (method C; ESI, m/z) tR = 0.57 min 
(purity:>98%) – 325 [(M+H)+]; HRMS (method D): found 325.1787; calculated for 
C17H21N6O (M+H)+ 325.1777.  
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Legends for Figures: 
Figure 1: Reported KDM inhibitors 
Figure 2: Overlay of crystal structures of 16a bound to KDM4A (light orange), and KDM5B 
(cyan). Compound 16a is shown in ball and stick representation and protein backbone chains 
are represented as cartoon tubes, with key amino acid side-chains displayed in line 
representation. Metal ions are shown as spheres. Labels highlight residues that are different 
between KDM4A (black) and KDM5B (cyan). KDM5B loop 91-100 is not displayed due to 
its construct-derived artefactual position as discussed in Figure S1. 
Figure 3: A) Overlay of crystal structures of 1 (2,4-PDCA, blue, PDB 2VD7) and 16a 
(beige) bound to KDM4A. B) Overlay of crystal structures of 1 (2,4-PDCA, orange, PDB 
5A3W) and 16a (cyan) bound to KDM5B. Metal ions are shown as spheres. Protein 
backbone chains are represented as cartoon tubes, key residues are displayed in line 
representation. Compounds 1 (2,4-PDCA) and 16a are shown in ball and stick representation. 
KDM5B loop 91-100 is not displayed due to its construct-derived artefactual position as 
discussed in Figure S1.  
Figure 4: Overlay of crystal structures of 16m (green) and 16a (beige) bound to KDM4A. 
Protein backbone chains are represented as cartoon tubes, key residues are displayed in line 
representation. Compounds 16m and 16a are shown in ball and stick representation. The two 
methyl groups in 16m have not been modelled due to too weak density linked to the high 
mobility of the corresponding atoms. Metal ions are shown as spheres.  
Figure 5: Overlay of crystal structures of 17b (pink), 17e (magenta) and 17f (light-green) 
bound to KDM4A. Zn(II) atoms are shown as grey spheres. Protein backbone chains are 
represented as cartoon tubes, key residues are displayed in line representation. The pyridyl 
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ring in 17b has not been modelled due to too weak density of the corresponding atoms. 
Compounds 17b, 17e and 17f are shown in ball and stick representation. 
Figure 6: Overlay of crystal structures of 18a (brown) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as grey spheres. Proteins backbone chains are represented as cartoon 
tubes, key residues are displayed in line representation. Compounds 18a and 16a are shown 
in ball and stick representation. 
Figure 7: Overlay of crystal structures of 19a (grey) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, 
key residues are displayed in line representation. Compounds 19a and 16a are shown in ball 
and stick representation. 
Figure 8: Overlay of crystal structures of 19d (pink) and 16a (beige) bound to KDM4A. 
Zn(II) are shown as spheres. Proteins backbone chains are represented as a cartoon tubes, key 
residues are displayed in line representation. Compounds 19d and 16a are shown in ball and 
stick representation. 
Figure 9: Overlay of crystal structures of 34a (blue) and 16a (beige) bound to KDM4A. 
Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, 
key residues are displayed in line representation. Compounds 34a and 16a are shown in ball 
and stick representation. 
Figure 10: A: Overlay of crystal structures of 34a (blue) and 34b (green) bound to KDM4A. 
Chains A and B of the asymmetric unit are shown for 34b-KDM4A structure, as they do not 
show exactly the same conformation for the ligand and its neighbouring protein residues. B: 
Overlay of crystal structures of 34a (blue) and 34g (pink) bound to KDM4A. Chains B and D 
of the asymmetric unit are shown for 34g-KDM4A structure, as they do not show exactly the 
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same conformation of the protein. Zn(II) atoms are shown as grey spheres. Protein backbone 
chains are represented as cartoon tubes, key residues are displayed in line representation. 
Compounds are shown in ball and stick representation. The distal methyl group in 34b has 
not been modelled due to too weak density linked to the high mobility of the corresponding 
atoms.  
Figure 11: 2OG co-substrate competition studies for 19a in KDM4A, KDM4B and KDM5B 
biochemical assays. 
Figure 12: KDM4A and KDM5B target engagement in HeLa cells by 19a and its matched 
pair inactive control 41 based on modulation of the relevant histone methyl mark (IF assay). 
Constructs encoding FLAG-tagged wild type KDM4A or catalytically inactive mutant 
(H188A/E190A) KDM4A, and wild type KDM5B or catalytically inactive mutant 
(H499A/E501A) KDM5B were used. 
Legends for Schemes: 
Scheme 1 
aReagents and conditions: (a) (i) methanesulfonic anhydride, anhydrous CH2Cl2, 0 °C, 15 
min, work-up, (ii) triethylamine, C4-substituted piperidine, anhydrous DMF, 50 °C, 15 h; (b) 
C4-substituted piperidine, anhydrous 1,2-dichloroethane or CH2Cl2, NaBH(OAc)3, room 
temp.; (c) 6 M HCl, THF, 50 to 60 °C, 3 to 8 h or 4 M HCl in dioxane, H2O, 50 °C. 
 
Scheme 2 
aReagents and conditions: (a) aryl/heteroaryl halide, Pd(dppf)Cl2, DME, 1 M aqueous 
Na2CO3, microwave, 120 °C, 45 min; (b) (i) Pd(OH)2 on carbon, EtOH, 1 M HCl, H2, room 
temp 1 h or 10% Pd/C, EtOH, H2, room temp, 2 h, (ii) when R = Boc: 4 M HCl in dioxane, 
room temp, 2 h or when R = Cbz: AcOH, 10% Pd/C, H2, room temp, 4 to 6 h. 
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Scheme 3 
aReagents and conditions: (a) (i) LiN(SiMe3)2 (1M solution in THF), THF, 0 °C, 45 min, (ii) 
tert-butyl bis(2-chloroethyl)carbamate, 0 °C, 2 h; (b) 10% Pd/C, EtOH, H2, room temp, 2 h; 
(c) 4 M HCl in dioxane, room temp, 2 h. 
 
Scheme 4 
aReagents and conditions: (a) aldehyde, NaBH(OAc)3, DMF, room temp, stirring up to 6 h; 
(b) Cs2CO3, anhydrous MeCN, 8-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-
d]pyrimidin-4(3H)-one, reflux, 18 h; (c) 6 M HCl, THF, 50 to 60 °C, 3 to 8 h. 
 
Scheme 5 
aReagents and conditions: (a) (i) 2.5 M nBuLi in hexane, THF, -78 °C to room temp (1.5 h) 
then cool to -78 °C, (ii) 1-methylpiperidin-4-one, warm up to room temp, 1.5 h, then 
AcOH/TFA, 90 °C, 4 h; (b) 10% Pd/C, EtOH, 1 M HCl, H2, 16 h. 
 
Scheme 6 
aReagents and conditions: (a) triethylamine, anhydrous DMF, 50 °C, 15 h; (b) 6 M HCl, THF, 
50 °C, 3 h. 
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Highlights 
 
• Targeting of KDM4A residues E169 and V313 to improve affinity for the KDM4-
subfamily. 
• Potent and cell-penetrant KDM4/5-subfamily inhibitors such as 19a were identified. 
• Significant drop from biochemical to cell-based activity was observed. 
• Lower potency in cells is linked to competition with the 2OG co-substrate. 
 
 
 
 
 
 
